View Volibris overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Swallow whole, do not chew/crush/split.
Contraindications
Hypersensitivity to ambrisentan & soya. Idiopathic pulmonary fibrosis, w/ or w/o secondary pulmonary HTN. Severe hepatic impairment (w/ or w/o cirrhosis). Baseline values of AST &/or ALT >3 x ULN. Women of childbearing potential who are not using reliable contraception. Pregnancy & lactation.
Patients w/ WHO functional class I & IV PAH. Risk of reduction in Hb conc & haematocrit; peripheral oedema; pulmonary veno-occlusive disease. Evaluate ALT & AST prior to therapy. Discontinue in case of clinically significant ALT &/or AST elevation or if ALT &/or AST elevation is accompanied by signs or symptoms of hepatic injury. Concomitant use w/ rifampicin. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Contains Allura red AC Aluminium Lake (E129) & lecithin derived from soya. Severe renal or hepatic impairment. May affect male fertility. Minor or moderate influence on the ability to drive & use machines. Childn & adolescents <18 yr.
Increased exposure w/ cyclosporine A. Transient increase in exposure w/ rifampicin. Use w/ caution when co-administered w/ other treatments for PAH (eg, prostanoids & soluble guanylate cyclase stimulators).
Sign Out
